In a recently published congress abstract of a phase 1 study of volixibat in overweight and obese adults [51], volixibat increased faecal BA and serum C4 levels compared with placebo, indicating that these PD effects are consistent across studies and occur in a patient population that is characteristic of NASH. The gene discussed is C4A; the disease is metabolic dysfunction-associated steatohepatitis.